LY451395| CAS 375345-95-2

Cas No.:	375345-95-2
Chemical Name:	Mibampator
Synonyms:	MIBAMPATOR;N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide;{(2R)-2-[4-(4-{2-[(methylsulfonyl)amino]ethyl}phenyl)phenyl]propyl}[(methylet;2-Propanesulfonamide, N-((2R)-2-(4'-(2-((methylsulfonyl)amino)ethyl)(1,1'-biphenyl)-4-yl)propyl)-;2-PROPANESULFONAMIDE, N-[(2R)-2-[4'-[2-[(METHYLSULFONYL)AMINO]ETHYL][1,1'-BIPHENYL]-4-YL]PROPYL]-;CHEMBL1277001;CTK4H8360;LY 451395;LY-451395;Mibampator [USAN:INN];N-[(2R)-2-[4'-[2-[(Methylsulfonyl)amino]ethyl][1,1'-biphenyl]-4-yl]propyl];UNII-A9V5BW73UU;[(2R)-2-[4-[4-[2-[(Methylsulfonyl)amino]ethyl]phenyl]phenyl]propyl][(1-methylethyl)sulfonyl]amine;LY451395;AKOS027338712;MIBAMPATOR [WHO-DD];(R)-N-(2-(4'-(2-(Methylsulfonamido)ethyl)-[1,1'-biphenyl]-4-yl)propyl)propane-2-sulfonamide;BDBM50330415;LY-451395; LY451395; Mibampator;NS00068333;NCGC00390642-01;Mibampator (USAN/INN);375345-95-2;CS-3166;A9V5BW73UU;((2R)-2-(4-(4-(2-((METHYLSULFONYL)AMINO)ETHYL)PHENYL)PHENYL)PROPYL)((1-METHYLETHYL)SULFONYL)AMINE;N-[(2R)-2-[4-[4-[2-(methylsulfonylamino)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide;BCP28335;HY-10934;(R)-N-(2-(4''-(2-(methylsulfonamido)ethyl)biphenyl-4-yl)propyl)propane-2-sulfonamide;D09931;SCHEMBL3045499;DB12717;MS-27869;DA-55465;DTXSID20190977;N-((2R)-2-(4'-(2-((Methylsulfonyl)amino)ethyl)biphenyl-4-yl)propyl)propane-2-sulfonamide;BRD-K42981054-001-01-9;8SO;MFCD18251566;MIBAMPATOR [USAN];MIBAMPATOR [INN];Q27273819
SMILES:	C[C@@H](CNS(C(C)C)(=O)=O)C1=CC=C(C2=CC=C(CCNS(C)(=O)=O)C=C2)C=C1
Formula:	C₂₁H₃₀N₂O₄S₂
M.Wt:	438.6039
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A potent, selective, and centrally active positive allosteric modulator of AMPAR-mediated neurotransmission, which increase ion channel flux in the presence of agonist by suppressing desensitization and/or deactivation of the receptors.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714	S3226	S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.